‘$1B Here We Come’: Congressional Memos Expose Shkreli’s Emails About Price Hikes
Ahead of Thursday's House Oversight and Government Reform Committee hearing on drug costs, congressional Democrats release documents from former Turing CEO Martin Shkreli and others that reveal how the company planned to maximize profits and control public perception.
The New York Times:
Martin Shkreli All But Gloated Over Huge Drug Price Increases, Memos Show
The Wall Street Journal:
Valeant, Turing Boosted Drug Prices To Fuel Preset Profits
NPR:
A Peek Inside Turing Pharmaceuticals: 'Another $7.2 Million. Pow!'